1. To study the interaction between low-density lipoprotein (LDL) and granules from rat serosal mast cells in vitro, mast cells were stimulated with the degranulating agent 48/80 to induce exocytosis of the secretory granules. Subsequent incubation of the exocytosed granules with 125I-LDL resulted in binding of the labelled LDL to the granules. When increasing amounts of agent 48/80 were added to mast-cell suspensions, a dose-dependent release of granules was observed and a parallel increase in the amount of 125I-LDL bound to granules resulted. 2. 125I-LDL bound to a single class of high-affinity binding sites on the granules. At saturation, 105 ng of LDL were bound per ,ag of granule protein. 3. The lipoprotein binding to mast-cell granules was apolipoprotein(apo)-B+E-specific. Thus 125I-LDL binding to the granules was effectively competed for by LDL (apo-B) or by dimyristoyl phosphatidylcholine vesicles containing apo-E, but not by high-density lipoprotein (HDL3) containing apo-AI as their major protein component. 4. Neutralization by acetylation of the positively charged amino groups of apo-B of LDL or presence of a high ionic strength in the incubation medium prevented LDL from binding to the granules, indicating the presence of ionic interactions between the positively charged amino acids of LDL and negatively charged groups of the granules. 5. It could be demonstrated that LDL bound to the negatively charged heparin proteoglycan of the granules. Thus treatment of granules with heparinase resulted in loss of their ability to bind LDL, and substances known to bind to heparin, such as Toluidine Blue, avidin, lipoprotein lipase, fibronectin and protamine, all effectively competed with LDL for binding to the granules. The results show that LDL is efficiently bound to the heparin proteoglycan component of mast-cell granules once the mast cells are stimulated to release their-gran-ules into-the extraceHular space.
INTRODUCTION
The role of mast cells in the immediate-type hypersensitivity reactions is well established. On antigen challenge, the mast cells are activated and release specific cytoplasmic organelles, the secretory granules, into the extracellular space (Ishizaka & Ishizaka, 1984) . The granules contain preformed mediators of the immediatetype hypersensitivity reactions such as histamine and, in addition, proteolytic enzymes embedded in a heparin proteoglycan matrix. Most of the mediators stored in the secretory granules are freely soluble in physiological buffers (Schwartz & Austen, 1984) . Hence, after degranulation of mast cells or after suspending purified granules in physiological buffers, the soluble mediators are released from the granules. In contrast, the major protein component of granules, composed of neutral proteinases, is not released but instead remains tightly bound to the heparin proteoglycan matrix of the granules (Schwartz & Austen, 1984) . The function of the formed insoluble heparin-proteinase complexes, i.e. of extracellular granules, has remained obscure.
We have recently found that the extracellularly located granules of mast cells are able to interact with LDL by degrading the apo-B component of LDL (Kokkonen & Kovanen, 1985) . The present studies were designed to test whether LDL binds to the granules, and if so, whether LDL, known to bind to various glycosaminoglycans, including heparin (Iverius, 1972) , would bind to the heparin proteoglycan of the mast-cell granules. The results indicate that LDL is able to bind to the mast-cell granules once the granules are released from mast cells into the extracellular space, and that it is the heparin proteoglycan of the granules to which LDL binds on formation of an LDL-granule complex.
MATERIALS AND METHODS Materials and animals
Na125I (13-17 mCi//tg) and Na235SO4 (> 5 mCi/, ug) were purchased from Amersham International. Heparinase (500 units/mg of protein), avidin, 2-mercaptoethylamine (cysteamine), bovine serum albumin and soybean trypsin inhibitor were obtained from Sigma. Toluidine Blue was purchased from Fluka. DMPC was obtained from KSV-Chemicals Ltd. Dulbecco's PBS was purchased from Gibco. Fibronectin from human plasma was kindly given by Dr. Antti Vaheri, Department of Virology, University of Helsinki, Helsinki, Finland. Lipoprotein lipase from bovine milk, and purified human apo-E2 and apo-AI were kindly given by Dr. Timo Kuusi, Third Department of Medicine, University of Helsinki, Helsinki, Finland. Compound 48/80 was kindly given by AB Leo. Male Wistar rats weighing between 300 and 500 g were obtained from Orion Ltd.
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They were kept in constant light and were provided with water and laboratory chow (Orion Ltd.) ad libitum. Isolation of mast cells and mast-cell granules The isolation of the rat serosal mast cells (i.e. mast cells from peritoneal and pleural cavities) was performed by density-gradient centrifugation in Ficoll as described previously (Kokkonen & Kovanen, 1985) . Mast-cell granules were isolated from purified mast cells as described previously (Kokkonen & Kovanen, 1985) . The amount of granules is expressed in terms of granule protein.
Preparation of 35S-labelled granules
The heparin component of mast-cell granules was radiolabelled in vitro by incubating purified rat mast cells [(5-10) x 106] with 1 mCi of Na 35SO4 for 4 h as previously described by Yurt et al. (1977) . After incubation the granules were isolated as described above. 35S-labelled material in mast-cell granules was identified as heparin by treating the granules with heparinase (Linker & Hovingh, 1972) . For this purpose, the 35S-labelled granules were incubated with heparinase in buffer C [100 mM-sodium acetate (pH 7.0)/1.0 mMcalcium acetate/bovine serum albumin (1 mg/ml)/ soybean trypsin inhibitor (2.5 mg/ml)] at 37°C for 15 min. To separate the 35S-labelled degradation products from granules, the granules were sedimented by centrifuging at 12000 g for 5 min and the amounts of 35S radioactivity in the supernatants and in the granule pellets were measured (LKB-Wallac RackBeta 1215 liquid-scintillation counter). The extent of heparin degradation by heparinase is expressed as the percentage of 35S-labelled material released from the granules into the supernatants. Similar values for the extent of heparin degradation could also be obtained if the 35S-labelled degradation products were separated from the granules by gel filtration on a Sepharose 4B column (Pharmacia) (Atkins et al., 1985) . Therefore the 35S radioactivity present in the supernatants could be used as a quantitative measure of degradation of granule heparin. Preparation and iodination of lipoproteins Human lipoprotein fractions were prepared from the plasma of fasted healthy donors as previously described (Kokkonen & Kovanen, 1985) . LDL [d (relative density) = 1.019-1.050) and HDL3 (d = 1.125-1.215) were fractionated by sequential ultracentrifugation (Havel et al., 1955) using solid KBr for density adjustment (Radding & Steinberg, 1960 (McFarlane, 1958; Bilheimer et al., 1972) as previously described (Kokkonen & Kovanen, 1985) . The ranges of the specific radioactivities of 125I-LDL were 100-220 c.p.m./ng of protein. Preparation of apolipoprotein-DMPC complexes Apo-E2 was first treated with cysteamine to convert the cysteine residues of the apo-E2 into positively charged lysine analogues (Weisgraber et al., 1982) . DMPC vesicles were prepared by the procedure of Roth et al. (1977) . The gradient-gel electrophoresis of the apo-E-DMPC and apo-AI-DMPC complexes showed single bands of apo-E and apo-AI respectively. Binding of 1251-labelled lipoproteins to mast-cell granules The standard binding assay was conducted in 90 #1 of buffer A [150 mM-NaCl/bovine serum albumin (10 mg/ ml)/soybean trypsin inhibitor (1.2 mg/ml)/ 5 mMTris/HCI, pH 7.4], containing the granules (2.5-20 jug of granule protein), and the indicated concentrations of 1251-labelled or unlabelled lipoproteins. Neither bovine serum albumin nor trypsin inhibitor influenced the binding of 1251-LDL to the granules. The binding reactions were initiated by adding the granules, and the incubations were carried out at 0°C in stoppered plastic tubes in an ice bath for the indicated times. To determine the amount of granule-bound labelled lipoproteins, a portion (80 ,ul) of the reaction mixture was layered on to 170 ,1 of medium consisting of 0.25 M-sucrose, bovine serum albumin (10 mg/ml) and 5 mM-Tris/HCl, pH 7.4. The tubes were then centrifuged at 12000 g for 15 min at 4 'C. The supernatant of each tube was removed by aspiration and the area of the tube containing the granule pellet was sliced with a scalpel and counted for its 1251 radioactivity (LKB-Wallac CliniGamma 1272 y-radiation counter). The results are expressed as ng of LDL protein bound per ,tg of granule protein.
Other assays
Histamine was determined by fluorimetry as described previously (Kokkonen & Kovanen, 1985) . Protein was determined by the procedure of Lowry et at. (1951) , with bovine serum albumin as a standard.
The results given in the Figures are representative of experiments repeated at least three times.
RESULTS

Binding of 1251-LDL to exocytosed mast-cel granules
To induce specific and non-cytotoxic degranulation of mast cells, i.e. exocytosis of secretory granules, we treated mast cells with the compound 48/80 (5 ,sg/ml) (R6hlich et al., 1971) . To demonstrate the extrusion of the granules, the cells were removed by centrifugation (150 g for 5 min), and the supernatants were centrifuged at a centrifugal force (12000 g for 15 min) sufficient to sediment granules. The presence of granules in the 12000 g sediment could be verified by measuring the activity of the proteolytic enzyme chymase in the sediment. Chymase, the major proteolytic enzyme of the granules, is not released from the granules after degranulation and can thus be used as a granule marker (Schwartz & Austen, 1984) . All of the chymase activity present originally in the 150 g supernatant could be recovered in the 12000 g sediment, demonstrating quantitative sedimentation of the released granules at the given centrifugal force (results not shown). In addition, electron-microscopic examination showed that the 12000 g sediment consisted solely of mast-cell granules. When the resuspended 12000 g sediment (granules) was granules suggested that the labelled LDL bound to the granules, i.e. that complexes between LDL and the granules were formed. When the above experiment was repeated using increasing amounts of compound 48/80, increasing amounts of histamine were released into the incubation medium, reflecting a dose-dependent exocytosis of mast-cell granules (Fig. la) . The abilities of the various amounts of released granules to form complexes with LDL was then quantified by measuring the cosedimentation of labelled LDL and the granules. It appeared that the formation of LDL-granule complexes closely paralleled the increase in histamine release, i.e. the release of granules into the extracellular space (Fig. lb) . At maximal stimulation of degranulation, the amount of histamine in the extracellular space was 5.7-fold higher and the amount of LDL-granule complexes formed was 6.2-fold higher than without stimulation. Hence, a quantitative relationship between the amount of granules released and the amount of formation of LDL-granule complexes could be established. Characteristics of 1251-LDL binding to isolated mast-cell granules
The above experiments demonstrated that, after stimulation of mast cells, the exocytosed mast-cell granules are able to bind 1251-LDL. To examine the binding phenomenon in more detail, we conducted a series of experiments with isolated mast-cell granules obtained from lysed mast cells, a method which yields large amounts of granules (Thon & Uvniis, 1966) . Since mast-cell granules are also able to interact with LDL by degrading it (Kokkonen & Kovanen, 1985) , we carried out the experiments at 0°C to be able to study binding alone without concomitant degradation of 125I-LDL.
When 125I-LDL was incubated with isolated mast-cell granules at 0°C, the labelled lipoprotein was rapidly bound to the granules, with equilibrium achieved in less than 1 min. On incubation of granules with increasing concentrations of 125I-LDL a two-component saturation curve for the binding was obtained (Fig. 2a) . The high-affinity component of this binding curve showed evidence of saturation at about 25 ,ug ofLDL protein/ml. At higher concentrations of 1251-LDL a small nonsaturable component of the binding curve became apparent. When the binding reaction was conducted in the presence of excess unlabelled LDL, the high-affinity component of the 1251-LDL binding curve was abolished, indicating that the unlabelled LDL was competing with the 1251-LDL for a limited number of binding sites.
The difference between the 125I-LDL binding in the absence and the presence of excess unlabelled LDL gives a measure of the high-affinity binding. A Scatchard plot of the high-affinity binding curve produced a straight line with intercepts giving a value of 6 ,ug of LDL protein/ml (equivalent to 10 nM-LDL) for the concentration of 1251-LDL producing half-maximal binding (Fig. 2b) . The maximal binding was 105 ng//utg of granule protein.
When the above experiment was repeated at 37°C in the presence of soybean trypsin inhibitor to prevent LDL degradation (Kokkonen & Kovanen, 1985) (Mr 2.6 x 106) is 24%, it could be calculated that, at saturation, each granule bound approx. 5000 particles of LDL.
To test the effect of apo-B modifications on LDL binding to mast-cell granules, LDL was treated with either acetic anhydride (Basu et al., 1976) or with cyclohexanedione (Mahley et al., 1977) to yield LDL in which the positively charged groups of lysine or arginine respectively are neutralized. The binding of acetyl-1251-LDL and cyclohexanedione-125I-LDL to mast-cell granules was totally abolished (results not shown), demonstrating the critical role of positively charged amino acids of apo-B in the observed binding phenomenon.
The above results suggested the presence of ionic interactions between the positively charged groups of LDL and negatively charged groups of the granules. To study the presence of ionic interactions, the binding of 125I-LDL to mast-cell granules was tested at NaCl ionic strengths of up to 0.5 (500 mM-NaCl). Under these experimental conditions the sedimentation of granules was not influenced (measured using 35S-labelled granules). As shown in Fig. 3 After incubation at 0°C for 60 min, the amounts of 125I-LDL bound to granules were determined. The 100% control value for 1251-LDL bound in the absence of apolipoprotein-DMPC complexes was 11 ng/,ug of granule protein.
Apolipoprotein specificity of lipoprotein binding to mast-cell granules After having defined the role of apo-B in the binding of LDL to mast-cell granules, we studied whether lipoproteins devoid of apo-B would also bind to the granules. For this purpose we compared the abilities of LDL (apo-B) and of HDL3 (devoid of apo-B and apo-E) containing apo-AI as its major protein component to compete with 125I-LDL for binding to the granules. As shown in Fig. 4(a) , the binding of 1251-LDL was effectively competed for by unlabelled LDL but not by unlabelled HDL3. In addition we could show that 1251-HDL3 completely lacked the ability to bind to mastcell granules (results not shown).
To study further the apolipoprotein specificity of the binding phenomenon, we prepared apolipoprotein-DMPC complexes containing either purified human apo-E or apo-AT, and compared their abilities to compete with 125I-LDL for binding to mast-cell granules (Fig. 4b) . It appeared that the binding of the labelled LDL to the granules could be .competed for by the apo-E-DMPC complexes, but not by the apo-AI-DMPC complexes. The above results with lipoproteins and apolipoprotein-DMPC complexes revealed specificity of the binding phenomenon in that the apolipoproteins B and E, but not Al, are able to bind to mast-cell granules.
Characterization of the LDL-binding site on mast-cell granules
In the final series of experiments we studied the nature of the binding site responsible for the observed binding of the apolipoqpoteins B and E to mast-cell granules. The mast-cell granuYes are known to contain a negatively charged heparin proteoglycan (Schwartz & Austen, 1984) which, by virtue of its negative charge, might have interacted with the positively charged amino acids of apo-B and apo-E (Mahley et al., 1979) . To test this hypothesis we treated mast-cell granules with heparinase, an enzyme known to degrade heparin specifically (Linker & Hovingh, 1972) . To be able to quantify the degradation of granule heparin, we labelled the sulphate groups of heparin with 35S (Yurt et al., 1977) . When the 35S-labelled granules were incubated with heparinase to yield maximal degradation of granule heparin (77% loss of 35S label), and then allowed to bind 1251I-LDL, it was found that the amount of LDL binding was on average only 21 % of that obtained with untreated 35S-granules (Fig. 5 ). This result indicated that granule heparin was essential for binding of LDL to the granules. In a control experiment we could demonstrate that chondroitinase ABC had no effect on the binding of 1251-LDL to mast-cell granules (results not shown).
To demonstrate by another method that the binding site on mast-cell granules is heparin, we conducted a series of competition experiments with compounds known to interact with mast-cell-granule heparin or commercial heparin. For this purpose the granules were incubated with Toluidine Blue or avidin, both known to bind to mast-cell-granule heparin (Jaques, 1967; Tharp et al., 1985) , or with lipoprotein lipase or plasma fibronectin, both known to bind to commercial heparin (Olivecrona et al., 1971; Stathakis & Mosesson, 1977) . All of the compounds tested, i.e. Toluidine Blue and avidin (Fig. 6a) , as well as lipoprotein lipase and plasma fibronectin (Fig. 6b) saturating concentrations of LDL, the granules did bind, in terms of total weights, about 300 ng of LDL per ,tg of granules, i.e. an amount equal to one-third of their weight. Such high binding capacity can be well explained by the high heparin content of the granules. Indeed, in physiological buffers where the soluble mediators are released from the granules, at least 35% of the total weight of the granules is composed of heparin (Schwartz & Austen, 1984) .
LDL is known to form complexes with several commercially available (low-Mr) glycosaminoglycans, including heparin. Among the glycosaminoglycans tested, heparin demonstrated the highest affinity for LDL (Iverius, 1972) . LDL may form complexes also with various naturally occurring proteoglycans. In fact, the interaction of arterial proteoglycans and LDL has been postulated to be an important factor in the entrapment of LDL and the resulting extracellular deposition of lipid in the arterial wall (Berenson et al., 1984) . However, unlike other naturally occurring proteoglycans, the heparin proteoglycan is not normally found in the extracellular space (Fransson, 1985) . Heparin proteoglycan is an intracellular proteoglycan that is synthesized exclusively in mast cells and stored in their cytoplasmic granules (Fransson, 1985) . Consequently, stimulation of mast cells and the ensuing degranulation are required for the extracellular LDL-heparin proteoglycan complexes to form.
The fate of the exocytosed mast-cell granules has remained obscure. Recent studies in vitro have demonstrated, however, that mast-cell granules can be phagocytosed and eventually degraded by arterial endothelial cells (Atkins et al., 1985) , by cultured fibroblasts (Subba Rao et al., 1983) , and by macrophages (Lindahl et al., 1979) . If, also, the LDL-granule complexes could be phagocytosed by these cells, then cellular uptake of LDL would follow. It remains to be elucidated whether such uptake mechanism could play a role in the accumulation of LDL cholesterol by macrophages, a phenomenon characteristic of atherosclerosis.
